ArticlePharmaceutics2021

Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial.

Ewelina Juszczyk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.